InvestorsHub Logo
Followers 32
Posts 2803
Boards Moderated 3
Alias Born 10/24/2015

Re: NY1972 post# 261

Thursday, 05/11/2023 6:49:22 PM

Thursday, May 11, 2023 6:49:22 PM

Post# of 386
No, but with NKs you can have a multi-antigen targeting strategy to tackle solid tumour heterogeneity. In this, FATE a MICA/B-targeted CAR-NK was combined with mAbs/engagers, which showed improved activity https://jitc.bmj.com/content/10/Suppl_2/A217

That could have been built on with additional CAR(s), membrane-bound TRAIL variant, FasL, and/or synthetic receptors, such as this https://ashpublications.org/blood/article/140/Supplement%201/7429/491146/A-CD3-Fusion-Receptor-CD3-FR-Uniquely-Enables
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FATE News